Related Experiment Video
Updated: May 6, 2026
Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation
Published on: April 14, 2016
[Bone targeted therapies: new agents]
Claire Barth1, Christophe Massard, Stéphane Vignot
1Groupe hospitalier Pitié-Salpêtrière - Charles-Foix, pôle ORPHé, 47-83, boulevard de l'Hôpital, 75013 Paris, France.
Abstract:
The development of bisphosphonates and anti-RANK/RANKL agents was associated with a better understanding of physiological and pathological processes of bone remodeling. New agents are now developed in this context targeting factors associated with osteoclastogenesis (TGFβ, PTHrP), with signaling pathways activated during bone remodeling (Src, Cathepsin K) or with tumor cells homing into bone (chemokines). This review aims to present the underlying rationale for these developments as well as the clinical results. The emergence of new bone targeting therapies is discussed.
Insights
New bone targeting therapies improve understanding of bone remodeling and osteoclastogenesis. This review covers agents targeting factors like TGFβ, PTHrP, Src, Cathepsin K, and chemokines for bone metastasis.
Area of Science:
- Bone biology and pharmacology
- Oncology and endocrinology
Context:
- Advances in understanding bone remodeling physiology and pathology.
- Development of bisphosphonates and anti-RANK/RANKL agents.
Purpose:
- Review the rationale and clinical results of novel bone-targeting therapies.
- Discuss emerging therapeutic strategies for bone remodeling and metastasis.
Summary:
- New agents target osteoclastogenesis factors (TGFβ, PTHrP), bone remodeling pathways (Src, Cathepsin K), and tumor cell homing (chemokines).
- Focus on therapies addressing bone metastasis and related pathological processes.
Impact:
- Informs clinical practice regarding new bone-targeting agents.
- Highlights future directions in bone metastasis treatment and bone remodeling modulation.
More Related Videos
07:00Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
Published on: September 26, 2016
11:47A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies